Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J Pediatric Infect Dis Soc. 2022 Jun 22;11(6):257-266. doi: 10.1093/jpids/piac011.
Pediatric international travelers account for nearly half of measles importations in the United States. Over one third of pediatric international travelers depart the United States without the recommended measles-mumps-rubella (MMR) vaccinations: 2 doses for travelers ≥12 months and 1 dose for travelers 6 to <12 months.
We developed a model to compare 2 strategies among a simulated cohort of international travelers (6 months to <6 years): (1) No pretravel health encounter (PHE): travelers depart with baseline MMR vaccination status; (2) PHE: MMR-eligible travelers are offered vaccination. All pediatric travelers experience a destination-specific risk of measles exposure (mean, 30 exposures/million travelers). If exposed to measles, travelers' age and MMR vaccination status determine the risk of infection (range, 3%-90%). We included costs of medical care, contact tracing, and lost wages from the societal perspective. We varied inputs in sensitivity analyses. Model outcomes included projected measles cases, costs, and incremental cost-effectiveness ratios ($/quality-adjusted life year [QALY], cost-effectiveness threshold ≤$100 000/QALY).
Compared with no PHE, PHE would avert 57 measles cases at $9.2 million/QALY among infant travelers and 7 measles cases at $15.0 million/QALY among preschool-aged travelers. Clinical benefits of PHE would be greatest for infants but cost-effective only for travelers to destinations with higher risk for measles exposure (ie, ≥160 exposures/million travelers) or if more US-acquired cases resulted from an infected traveler, such as in communities with limited MMR coverage.
Pretravel MMR vaccination provides the greatest clinical benefit for infant travelers and can be cost-effective before travel to destinations with high risk for measles exposure or from communities with low MMR vaccination coverage.
在美国,小儿国际旅行者占麻疹输入病例的近一半。超过三分之一的小儿国际旅行者离开美国时未接种推荐的麻疹-腮腺炎-风疹(MMR)疫苗:12 个月及以上旅行者接种 2 剂,6 至<12 个月旅行者接种 1 剂。
我们为一组模拟国际旅行者(6 个月至<6 岁)建立了一个模型,比较了两种策略:(1)无旅行前健康接触(PHE):旅行者离开时的基线 MMR 疫苗接种状况;(2)PHE:符合 MMR 条件的旅行者提供疫苗接种。所有小儿旅行者都面临特定目的地麻疹暴露风险(平均每百万旅行者 30 例暴露)。如果暴露于麻疹,旅行者的年龄和 MMR 疫苗接种状况决定感染风险(范围为 3%-90%)。我们从社会角度考虑了医疗费用、接触者追踪和旷工损失。我们在敏感性分析中改变了输入参数。模型结果包括预期的麻疹病例、成本和增量成本效益比(每质量调整生命年的美元数 [$/质量调整生命年(QALY)],成本效益阈值≤100000 美元/QALY)。
与无 PHE 相比,PHE 可使婴儿旅行者每百万旅行者中避免 57 例麻疹病例,每百万旅行者中节省 920 万美元/QALY;学龄前旅行者每百万旅行者中避免 7 例麻疹病例,每百万旅行者中节省 1500 万美元/QALY。PHE 的临床效益对婴儿最大,但仅对前往麻疹暴露风险较高的目的地(即≥160 例/百万旅行者)或如果更多的美国获得的病例是由受感染者引起的旅行者(如 MMR 覆盖率有限的社区)旅行时具有成本效益。
旅行前 MMR 疫苗接种可为婴儿旅行者提供最大的临床效益,并且可以在前往麻疹暴露风险较高的目的地或 MMR 疫苗接种覆盖率较低的社区之前具有成本效益。